Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Creative Medical Technology Holdings Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Creative Medical Technology Holdings Inc 주요 수익원은 Regenerative Therapies이며, 최신 수익 발표에서 수익은 6,000입니다. 지역별로는 United States이 Creative Medical Technology Holdings Inc의 주요 시장이며, 수익은 6,000입니다.
Creative Medical Technology Holdings Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Creative Medical Technology Holdings Inc의 순손실은 $0입니다.
Creative Medical Technology Holdings Inc에 부채가 있나요?
no, Creative Medical Technology Holdings Inc의 부채는 0입니다.
Creative Medical Technology Holdings Inc의 발행 주식은 몇 주인가요?
Creative Medical Technology Holdings Inc의 총 발행 주식은 0주입니다.